Raltegravir + Lopinavir/Ritonavir Versus Efavirenz + Tenofovir + Emtricitabine in Treatment Naive Patients

Exclusion Criteria

• •Pregnancy or breast-feeding
• •Serious illness requiring systemic treatment and/or hospitalization until subject either completes therapy or is clinically stable on therapy, in the opinion of the investigator, for at least 30 days prior to study entry (day 0).
• •Acute therapy for serious infection or other serious medical illnesses (in the judgment of the site investigator) requiring systemic treatment and/or hospitalization within 14 days prior to study entry (day 0).
• •Evidence of HIV seroconversion within 6 months prior to study entry.
• •Evidence of any major HIV drug resistance-associated mutation on any genotype performed prior to study entry or at the time of screening.
• •History of chronic hepatitis C (defined as HCV antibody positive and HCV RNA detectable).
• •History of chronic active hepatitis B (defined as surface antigen positive and/or HBV DNA detectable).
• •Active drug or alcohol use or dependence that, in the opinion of the investigator, would interfere with adherence to study requirements.
• •Use of any immunomodulator, HIV vaccine, or investigational therapy within 30 days of study entry.
• •Use of human growth hormone within 30 days prior to study entry.
• •Initiation of testosterone or anabolic steroids within 30 days prior to study entry. (Exception: Chronic replacement dosages in patient's with diagnosed hypogonadism is allowed).